Histogen Inc.: Nasdaq/NYSE listing notice — Histogen announces liquidation plan; Nasdaq to suspend trading Oct 5, 2023

Histogen Inc.

Board approved plan of dissolution; all clinical programs discontinued and workforce reduced to 2 employees effective Sep 30, 2023.
Nasdaq notified company on Sep 26, 2023 that it is deemed a 'public shell'; trading suspension effective Oct 5, 2023.
Company will not request a hearing; delisting and deregistration via Form 25-NSE to follow.
Stockholders must approve the Plan of Dissolution; no further timeline provided.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Histogen Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101

Exact text from the filing

September 26, 2023 by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, trading of the Company’s common stock will be suspended from trading at the opening of business on October 5, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel to address the deficiencies and present a plan to regain compliance. The Company does not plan to request a hearing and, therefore, expects that trading in the

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-049922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.